PAVM - PAVmed Inc Stock Price, Fair Value and News

$0.66-0.01 (-1.49%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PAVM Price Action

Last 7 days

1.5%


Last 30 days

4.8%


Last 90 days

-35.9%


Trailing 12 Months

-70.4%

PAVM Stock Price

Mar'24Jun'24Sep'24Dec'2401122334
$0.66

PAVM RSI Chart

MayJunJulAugSepOctNovDec20250102030405060708090

PAVM Valuation

Market Cap

7.3M

Price/Earnings (Trailing)

0.3

Price/Sales (Trailing)

1.95

EV/EBITDA

0.55

Price/Free Cashflow

-0.16

PAVM Price/Sales (Trailing)

20222023202420250100200300400500

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PAVM Fundamentals

PAVM Revenue

Revenue (TTM)

3.7M

Rev. Growth (Yr)

-11.5%

Rev. Growth (Qtr)

-28.5%

20222023202401M2M3M4M

PAVM Earnings

Earnings (TTM)

24.3M

Earnings Growth (Yr)

464.43%

Earnings Growth (Qtr)

694.8%

20162018202020222024-100M-80M-60M-40M-20M020M

PAVM Profitability

Operating Margin

-71.25%

EBT Margin

264.25%

Return on Equity

-259.12%

Return on Assets

79.62%

Free Cashflow Yield

-625.69%

PAVM Investor Care

Shares Dilution (1Y)

37.49%

Diluted EPS (TTM)

-4.28

Revenue Breakdown

As of: Sep 30, 2024
2022202320240200K400K600K800K1M
Total
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2022AprJulOct2023AprJulOct2024AprJul0500K1M1.5M2M2.5M3M3.5M4M
Net sales
YearQ1Q2Q3Q4
20243.0M3.8M3.7M0
2023634.0K800.0K1.5M2.5M
2022469.3K438.5K407.8K377.0K
2021000500.0K
Get all data in R, Python etc through our Historical Stock Data APIs
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
 CEO
 WEBSITEpavmed.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES124

PAVmed Inc Frequently Asked Questions


What is the ticker symbol for PAVmed Inc? What does PAVM stand for in stocks?

PAVM is the stock ticker symbol of PAVmed Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PAVmed Inc (PAVM)?

As of Fri Jan 31 2025, market cap of PAVmed Inc is 7.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PAVM stock?

You can check PAVM's fair value in chart for subscribers.

Is PAVmed Inc a good stock to buy?

The fair value guage provides a quick view whether PAVM is over valued or under valued. Whether PAVmed Inc is cheap or expensive depends on the assumptions which impact PAVmed Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PAVM.

What is PAVmed Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jan 31 2025, PAVM's PE ratio (Price to Earnings) is 0.3 and Price to Sales (PS) ratio is 1.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PAVM PE ratio will change depending on the future growth rate expectations of investors.